Curasight operates in the pharmaceutical industry. The company specializes in the development of technological products. The product portfolio has its main focus in the development of innovative technologies for the diagnosis and treatment of cancer based on targeted PET imaging and radionuclide therapy. The business is operated with the largest presence in Scandinavia. Curasight is headquartered in Copenhagen.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Curium International Trading B.V | 19,60 | 19,60 | 2025-08-04 |
| Andreas Kjær | 15,96 | 15,96 | 2025-08-04 |
| UK Curacap ApS | 11,62 | 11,62 | 2025-08-04 |
| Carsten Haagen Nielsen | 5,25 | 5,25 | 2025-08-04 |
| Pentwater Capital Management LP | 4,85 | 4,85 | 2026-02-03 |
| Nordnet Bank AB | 2,06 | 2,06 | 2025-08-04 |
| Jacob Madsen | 2,04 | 2,04 | 2025-08-04 |
| Avanza Bank AB | 1,58 | 1,58 | 2025-08-04 |
| Chr. Olesen Holding A/S | 1,54 | 1,54 | 2025-08-04 |
| Lars Trolle | 1,29 | 1,29 | 2025-09-01 |
2026-02-26 Year End Report 2025
2026-04-23 Interim Report 2026-Q1
2026-08-27 Interim Report 2026-Q2
2026-11-26 Interim Report 2026-Q3
